NCT05242861 (RetroBT) is a clinical trial of Brachytherapy in Brachytherapy, sponsored by Zhejiang Cancer Hospital.

Who is sponsoring NCT05242861?

NCT05242861 is sponsored by Zhejiang Cancer Hospital.

What drugs are being tested in NCT05242861?

Interventions in NCT05242861: Brachytherapy.

What condition does NCT05242861 study?

NCT05242861 studies Brachytherapy, Uterine Cervical Neoplasms, Uterine Neoplasms, Vulvar Cancer, Vaginal Cancer, Ovarian Neoplasms, Gynecologic Neoplasm.

Is NCT05242861 still recruiting?

NCT05242861 is currently recruiting now. Last updated 16 February 2022.

Last reviewed 2022-02-16 · How we verify

NCT05242861: RetroBT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Retrospective Study of Brachytherapy

Recruiting now Last updated 16 February 2022

What this trial tests

trial testing Brachytherapy in Brachytherapy in 300 participants. Currently enrolling.

Timeline

20 February 2022

Primary endpoint
31 December 2024

31 December 2027

Quick facts

Lead sponsor	Zhejiang Cancer Hospital
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	300
Start date	20 February 2022
Primary completion	31 December 2024
Estimated completion	31 December 2027
Sites	1 location across China

Drugs / interventions tested

Brachytherapy — full drug profile →

Conditions studied

Brachytherapy — all drugs for Brachytherapy →
Uterine Cervical Neoplasms — all drugs for Uterine Cervical Neoplasms →
Uterine Neoplasms — all drugs for Uterine Neoplasms →
Vulvar Cancer — all drugs for Vulvar Cancer →

Sponsor

Zhejiang Cancer Hospital

Who can join

Adults 18 to 80, female only, with Brachytherapy or Uterine Cervical Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Brachytherapy for gynecological cancers will be studied retrospectively.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A novel multi-channel applicator with a U-shaped channel for vaginal intracavity brachytherapy.
Lu Y, Chen J, Wang F, Zhou Q, et al · · 2024 · cited 1× · PMID 39259886 · DOI 10.1002/acm2.14521

Verify or expand the search:

Other trials of Brachytherapy

Trials testing the same drug.

NCT07061977 — Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance C · Phase 3 · recruiting
NCT07182279 — Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer · Phase 1, PHASE2 · recruiting
NCT06543576 — External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cer · Phase 1, PHASE2 · recruiting
NCT06333821 — A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma · Phase 3 · not yet recruiting
NCT06129851 — Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer · Phase 2 · not yet recruiting

Other recruiting trials for Brachytherapy

Currently open trials in the same condition.

NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
NCT05894018 — Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma · Phase 2 · recruiting
NCT06982469 — High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy · recruiting
NCT04071418 — I-125 Seeds Implantation in the Treatment of Recurrent Lung Cancer After Radiotherapy · recruiting

Other Zhejiang Cancer Hospital trials

Trials by the same sponsor.

NCT07343479 — Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases · Phase 2 · not yet recruiting
NCT07441720 — Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) · Phase 2 · recruiting
NCT07416890 — Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Ref · Phase 2 · recruiting
NCT07326150 — Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Canc · active not recruiting
NCT07330544 — A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Rec · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05242861 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang Cancer Hospital
Last refreshed: 16 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05242861.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing